This study assessed whether NLR or MLR could be a reliable predictor of survival for treatment-naive locally advanced or metastatic ESCC patients who had received PD-1/PD-L1 antibodies combined with chemotherapy as the first-line treatment. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.